 |
0 Companies | 0 Products |
|
|
0 Products | |
0 Diseases | |
0 Trials |  |
0 News |  |
- | Journal: Biotin Interference in Susceptible CanAg Ca242 Immunoassays and Elimination Method. (Pubmed Central) - Jun 22, 2021
The laboratory can overcome biotin interference on CanAg Ca242 by using a non-biotin streptavidin method or by absorbing biotin with streptavidin-coated microparticles before testing. Clinicians should use caution in interpreting abnormal results in patients who ingest biotin.
- || Biomarker, Clinical, Review, Journal: Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer. (Pubmed Central) - Jun 22, 2021
Clinicians should use caution in interpreting abnormal results in patients who ingest biotin. Serum CEA, CA24-2, and CA19-9 are valuable indicators for predicting the risk of colorectal cancer.
- | Biomarker, Journal: Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy. (Pubmed Central) - Jun 22, 2021
CEA and CA242 were significantly lower in the postoperative group than in the preoperative group. Serum DNA integrity index (ALU247/115) may prove to be a promising candidate biomarker for prognostic prediction of CRC who underwent chemotherapy and during short-term follow-up.
- || Clinical, Journal: Study of Fe₃O₄-PPy Core-Shell Nanocomposite in the Diagnosis of Tumor Markers in the Tissues of Early Gastric Cancer Patients. (Pubmed Central) - Jun 10, 2021
Therefore, it is believed that the Fe₃O₄-PPy is of great significance for the detection of early gastric tumor markers in the tissues of patients with early gastric cancer, and has certain value for the auxiliary diagnosis of early gastric cancer and the observation of therapeutic effects. This study results provide a reference for the further researches of Fe₃O₄-PPy in the diagnosis of tumor markers in patients with early gastric cancer.
- | Biomarker, Journal: Extracellular Vesicle-Transported Long Non-Coding RNA (LncRNA) X Inactive-Specific Transcript (XIST) in Serum is a Potential Novel Biomarker for Colorectal Cancer Diagnosis. (Pubmed Central) - May 28, 2021
XIST expression in serum EVs was positively correlated with CRC marker contents. CONCLUSIONS XIST upregulation in serum EVs is related to CRC progression, which may be helpful to the clinical diagnosis and prognosis of CRC.
- | Journal: Spatially-resolved dual-potential sandwich electrochemiluminescence immunosensor for the simultaneous determination of carbohydrate antigen 19-9 and carbohydrate antigen 24-2. (Pubmed Central) - May 15, 2021
Moreover, the ECL immunosensor possessed high selectivity and stability and successfully detected CA 19-9 and CA 242 in real samples. This immunosensor provides a new platform for clinical immunoassays.
- | Biomarker, Retrospective data, Journal: Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas. (Pubmed Central) - May 15, 2021
CA19-9 has a moderate ability, and CEA, CA125, and CA724 have a low ability to predict A-cMNs. The combination of STM testing could improve SE in predicting A-cMNs.
- | Biomarker, Journal: CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242. (Pubmed Central) - May 12, 2021
Furthermore, CA242 served as a better prognostic marker than both CEA and CA19-9. We recommend including both CA125 and CA242 in prognostic clinical trials among CRC patients.
- || Clinical, Journal: Overexpression of 14-3-3δ Predicts Poor Prognosis in Extrahepatic Cholangiocarcinoma Patients. (Pubmed Central) - Apr 29, 2021
Our results suggest that 14-3-3δ serves as an oncogenic driver in extrahepatic cholangiocarcinoma tumorigenesis rather than a cell cycle regulator; the overexpression of 14-3-3δ might be frequently acquired by tumor cells to escape appropriate cell cycle regulation. Thus, 14-3-3δ could be a potential target for extrahepatic cholangiocarcinoma diagnosis and therapy.
- | Journal: Performance evaluation of CA242 by flow fluorescence assay. (Pubmed Central) - Apr 29, 2021
No statistically significant difference between serum samples without interferences and samples containing lipemia, bilirubin and hemoglobin. And no cross reaction existed between the assay kit and the other tumor markers, such as carbohydrate antigen 125 (CA125), alpha-fetoprotein (AFP), and cytokeratin-19 soluble fragment (CYFRA21-1).The new CA242 quantitative assay kit possesses good detection performance when it is used in TESMI F3999-Luminex200 automatic immunoassay system, which can be used for the examination of CA242 in clinical practice.
- | Biomarker, Journal: Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. (Pubmed Central) - Apr 23, 2021
Taken together, this metabolomics method was used to identify and validate metabolite biomarkers that can precisely and sensitively diagnose the onsite progression and metastasis of pancreatic cancer in a clinical setting. Furthermore, such effort should leave clinicians with the correct time frame to facilitate early and efficient therapeutic interventions, which could largely improve the five-year survival rate of PC patients by significantly lowering clinical mortality.
- | Journal: Prognostic Value of Inflammatory and Tumour Markers in Small-Duct Subtype Intrahepatic Cholangiocarcinoma after Curative-Intent Resection. (Pubmed Central) - Apr 10, 2021
NLR and LMR, rather than platelet-to-lymphocyte ratio, were correlated with OS in small-duct type ICC. In addition, ferritin may be a supplement to CA19-9 in stratifying the survival outcome of patients with small-duct type ICC.
- | Biomarker, Retrospective data, Journal: Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study. (Pubmed Central) - Jan 30, 2021
In addition, ferritin may be a supplement to CA19-9 in stratifying the survival outcome of patients with small-duct type ICC. Our study found that adjuvant chemotherapy, PNLNR, intraoperative blood transfusion, tumor size, perineural invasion, serum CEA, and duration of hospital stay after surgery had significance in multivariate analysis and were independent risk factors for survival.
- | Journal: Feasibility of Plasma-Methylated SFRP2 for Early Detection of Gastric Cancer. (Pubmed Central) - Jan 14, 2021
In comparison, the sensitivity of methylated SFRP2 test for detecting GC was 58.2%. Plasma methylated SFRP2 test may become a valuable tool for the noninvasive detection of GC and precursor lesions and showed higher sensitivity than serum tumor markers.
- || Biomarker, Clinical, Journal: CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors. (Pubmed Central) - Dec 19, 2020
CD26 expression was significantly increased in pancreatic tumors and gradually increased with increasing malignancy degree, suggesting that CD26 may be involved in the tumorigenic proliferation of pancreatic tumors. Therefore, CD26 is a potential marker for early diagnosis and a promising therapeutic target in pancreatic tumors.
- || Clinical, Journal: Clinicopathological findings and imaging features of intraductal papillary neoplasms in bile ducts. (Pubmed Central) - Oct 20, 2020
Moreover, radical surgical resection could prolong patients' survival. Finally, differentiation degree was an independent risk factor affecting malignant IPNM-B prognosis.
- || Clinical, Journal: Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer. (Pubmed Central) - Jun 23, 2020
Besides, the combination of NSE, CEA, CA19-9, CA125 and CA242 was significantly more sensitive compared with NSE alone. Thus, the combined detection of the 5 tumor markers may be more useful for the diagnosis of CRC.
- | Biomarker, Journal: Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. (Pubmed Central) - May 23, 2020
Thus, the combined detection of the 5 tumor markers may be more useful for the diagnosis of CRC. These data reveal dysregulated lipids in serum exosome of PC patients, which have potential to be biomarkers for diagnosis, or unveil pathological relationship between exosome and PC progress.
- Tumor mutation burden combined with tumor markers as predictive prognostic biomarkers for neoadjuvant chemotherapy in patients with gastric cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1956;
TMB<5 together with TM+ was a strong and accessible biomarker of poor OS. This is the first report of TMB can be used as a predictive biomarker before NAC, and TMB combined with tumor markers (TM) were significantly associated with prognosis in patients with Gastric Cancer.
- | Biomarker, Journal: Correlation study between serum neuro-specific enolase and gastric and colorectal cancers. (Pubmed Central) - Apr 28, 2020
The AUC of the combined markers was higher than for any of the markers individually (0.778-0.810).The AUC for NSE alone suggests it may be an independent tumor marker, and useful for diagnosis of GC and CRC. However, the AUC for combined NSE, CEA, CA19-9, and CA242 was higher and thus potentially more diagnostic value.
- || Clinical, Journal: The prognostic value of preoperative serum CA724 for CEA-normal colorectal cancer patients. (Pubmed Central) - Apr 25, 2020
In the multivariate Cox regression analysis of OS and DFS, only pT stage, pN stage, metastasis and serum CA724 were independent prognostic risk factors for CRC patients with normal CEA levels. Preoperative serum CA724 might serve as a potential prognostic factor for CRC patients with normal serum CEA levels.
- || Biomarker, Clinical, Journal: Clinical significance of serum neuron-specific enolase in gastric adenocarcinoma. (Pubmed Central) - Apr 23, 2020
Besides, the combination of NSE, CEA, CA19-9, and CA242 performed even better than any single marker. Thus, the combined detection of the 4 tumor markers may be more useful for the diagnosis of gastric adenocarcinoma.
- | Journal, IO Biomarker: CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. (Pubmed Central) - Mar 24, 2020
High CXCL5 expression is positively correlated with poor survival and the increased infiltration of several types of immune suppressive cells. Thus, CXCL5 could be a promising therapeutic target for PDAC immunotherapy.
- || Clinical, Retrospective data, Journal: Analysis of clinicopathological features and prognosis of 1315 cases in colorectal cancer located at different anatomical subsites. (Pubmed Central) - Mar 8, 2020
Colorectal cancer at different anatomical subsites has different epidemiological, clinicopathological features and prognosis. Fully understanding the clinicopathological features of colorectal cancer at different anatomical subsites is of certain guiding significance for the clinical diagnosis and treatment of colorectal cancer, and is conducive to individualized treatment and accurate treatment.
- | Journal: Testicular Metastasis of Pancreatic Carcinoma on FDG-PET/CT. (Pubmed Central) - Mar 2, 2020
F-FDG PET/CT was recommended for identifying potential malignancy and showed several hypermetabolic masses in the pancreas, left testis, and right lung. Resection of left testicular and pancreatic masses and fine-needle biopsy of right pulmonary mass were performed, and subsequent pathology confirmed pancreatic adenocarcinoma metastasizing to the testis and lung.
- | Biomarker, Journal: The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. (Pubmed Central) - Feb 1, 2020
The reason is that most of the newly discovered cancer biomarkers are inferior in terms of sensitivity and specificity to these biomarkers. We will summarize the reported sensitivity and specificity of currently used cancer biomarkers, especially the glycan-related biomarkers, in the forms of tables and radar plots and discuss the pros and cons of currently used cancer biomarkers.
- | Biomarker, Retrospective data, Journal: Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years. (Pubmed Central) - Feb 1, 2020
Furthermore, the information shown as heatmap or waterfall built on the -Logp values of the 17 glycan-related biomarkers in different clinically defined diseases suggested that all glycan-related biomarkers had cancer-, aging-, and disease-relevant characteristics and cancers were systems disease. The detailed presentation of the data for each of the 17 biomarkers will be deliberated in chapters 6-23 in this book series.
- | Biomarker, Journal: CA242 as a biomarker for pancreatic cancer and other diseases. (Pubmed Central) - Feb 1, 2020
In contrast, patients suffering from sequela of brain damage and anemia had statistically lower median values than healthy controls. Based on the -logp values, the increased serum CA242 levels could be used not only for diagnosis of pancreatic and other cancers, but also for diagnosis of type 2 diabetes mellitus and coronary heart disease, suggesting CA242 might be a systemic malfunction biomarker associated with cancers and other chronic diseases.
- || Clinical, Journal: Possible involvement of HSP70 in pancreatic cancer cell proliferation after heat exposure and impact on RFA postoperative patient prognosis. (Pubmed Central) - Dec 25, 2019
This study found that a higher proliferative rate accompanied with a higher HSP70 expression level were observed on in vitro cultured pancreatic carcinoma cells after heat treatment, which could be altered by HSP70 inhibitor. And these findings indicated that the heat exposure might impact periphery carcinoma during RFA surgery and HSP70 might play an important role in patients' prognosis.
- || Biomarker, Clinical, Journal: Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer. (Pubmed Central) - Nov 19, 2019
Baseline bilirubin and serum proteins were not associated with the prognosis of advanced pancreatic cancer. Tumor location and level of CA19-9 may serve as significant indicators for poor prognosis in those patients.
- | Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Clinicopathological characteristics of type 2 diabetes mellitus complicated with colorectal cancer (Pubmed Central) - Oct 31, 2019
They have higher BMI and serum CEA level, and more Treg cell infiltration in the tumor. Close attention should be paid to these patients in clinical practice.
- | Biomarker, Clinical, Journal, Next-Generation Sequencing: Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer. (Pubmed Central) - Oct 17, 2019
Levels of the tumor serum marker CA242 in patients with ctDNA-detectable mutations were higher compared with those in patients without ctDNA-detectable mutations. The data from the present study highlight the importance of tissue and plasma ctDNA screening by NGS to guide personalized therapy and promote the clinical management of patients with NSCLC.
- | Journal: A Label-Free Electrochemical Immunosensor for Detection of the Tumor Marker CA242 Based on Reduced Graphene Oxide-Gold-Palladium Nanocomposite. (Pubmed Central) - Sep 22, 2019
More importantly, the immunosensor exhibited satisfactory reproducibility and selectivity when detected CA242 in PBS or human serum. The results of our study provide a platform for the development of novel bioassays for use in early cancer diagnosis and promote the application of biosensing technology in the medical field.
- | Biomarker, Journal: Identification of Serum Periostin as a Potential Diagnostic and Prognostic Marker for Colorectal Cancer. (Pubmed Central) - Sep 18, 2019
The results of our study provide a platform for the development of novel bioassays for use in early cancer diagnosis and promote the application of biosensing technology in the medical field. Serum POSTN might be a novel diagnostic and prognostic biomarker for patients with CRC.
- | Journal, Circulating Tumor Cells: Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer. (Pubmed Central) - Sep 10, 2019
Further analysis showed that the portal EpCAM+CD45- ratio ≥24.5×10 is a predictor of metastasis (P=0.025) in pancreatic cancer after curative resection. CTCs detected by FCM in portal venous blood are of significant value for the prediction of postoperative metastasis in pancreatic or periampullary tumors.
- | Biomarker, Clinical, Journal: Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study. (Pubmed Central) - Aug 31, 2019
PIVKA-II is significantly higher in PC than in benign pancreatic diseases. PIVKA-II shows a rather good diagnostic performance compared to CA 19-9, CEA and CA242, thus its determination could help PC management.
- | Journal: The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers. (Pubmed Central) - Jul 25, 2019
The number of increased tumor markers could significantly predict prognosis in stage II and III CRC. In addition, these increased tumor markers had direct impacts on metastasis as well as the recurrence status and survival time of stage II and III CRC patients.
- | Journal: Multifunctionalized ZIFs nanoprobe-initiated tandem reaction for signal amplified electrochemical immunoassay of carbohydrate antigen 24-2. (Pubmed Central) - Jun 26, 2019
Under optimal conditions, the proposed immunosensor displayed wide linear range from 0.001 to 1000 U mL with an ultralow limit of detection 69.34 μU mL (S/N = 3). This method successfully implemented functionalized ZIFs in immunoprobe construction for sensitivity amplification, providing a promising strategy to construct ultrasensitive immunosensing platform for analysis of other tumor marker.